Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels

Gynecol Oncol. 2006 Oct;103(1):137-40. doi: 10.1016/j.ygyno.2006.02.005. Epub 2006 Mar 27.

Abstract

Objective: To assess the value of routine periodic physical examination in the follow-up of ovarian (OvC) and primary peritoneal carcinoma (PPC) patients with pretreatment elevated CA125 levels.

Methods: Included were patients who had a pretreatment serum CA125 level above normal limits, had completed initial treatment, were in complete clinical remission on completion of the initial treatment and routinely attended the gynecologic oncology outpatient clinic. Recurrence was diagnosed when at least one of the following criteria was abnormal: symptoms, physical examination or elevated serum CA125 levels.

Results: Of 69 patients, a recurrence was diagnosed in 43. Abnormal physical examination for diagnosis of recurrence yielded a sensitivity rate of only 34.9%. The diagnosis of recurrence was based on an abnormal physical examination alone in 2 (4.6%) patients.

Conclusion: In OvC and PPC patients with elevated pretreatment CA125 levels, physical examination has a limited impact on the diagnosis of recurrence.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • CA-125 Antigen / blood*
  • Female
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local / blood
  • Organoplatinum Compounds / administration & dosage
  • Ovarian Neoplasms / blood*
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / surgery
  • Paclitaxel / administration & dosage
  • Peritoneal Neoplasms / blood*
  • Peritoneal Neoplasms / diagnosis*
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / surgery
  • Physical Examination

Substances

  • CA-125 Antigen
  • Organoplatinum Compounds
  • Paclitaxel